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IntroductIon
Androgen steroids play a key role in prostate cancer 
growth and development making the androgen-deprivation 
the principal therapeutic approach in the different stages of 
disease. However, hormone therapies lead to a transitory 
decrease in testosterone and dihydrotestosterone synthesis. 
Prostate cancer, especially in advanced disease, can only 
benefit temporarily from these treatments progressing 
to a castration-resistant prostate cancer (CRPC) status 
[1]. Despite this resistance to hormonal drugs, androgen 
signaling remains persistent, therefore targeting the androgen 
receptor pathway still continues to be a good therapeutic 
challenge for these patients [2]. Enzalutamide is a next 
generation anti-androgen with a great affinity for androgen 
receptor (AR) [3]. The results of two randomized phase 
3 trials on enzalutamide versus placebo in patients with 
CRPC before docetaxel treatment (Prevail study) and after 
docetaxel (Affirm trial), respectively, showed its efficacy 
in increasing progression-free survival (PFS) and overall 
survival (OS) [4, 5]. More recently, in two randomized 
phase 2 studies (Terrain study and Strive trial) enzalutamide 
significantly reduced risk of progression or death compared 
with bicalutamide in patients with asymptomatic or mildly 
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AbstrAct
In the present study, we aimed to evaluate the association of circulating AR 
copy number (CN) and outcome in a cohort of patients with advanced castration-
resistant prostate cancer (CRPC) treated with enzalutamide after docetaxel. Fifty-
nine CRPC patients were evaluated. AR CN was analyzed with real-time and digital 
PCR in the serum collected at starting of treatment. Progressive disease was defined 
on the basis of Prostate Cancer Working Group 2 criteria. AR CN gain was found in 
21 of 59 (36%) patients. Median baseline PSA, alkaline phosphatase and lactate 
dehydrogenase levels were higher in the AR CN gained group (p = 0.007, p = 0.003, 
p = 0.0009, respectively). Median PFS of patients with AR CN gain was 2.4 (95%CI: 
1.9−3.2) vs. 4.0 months (95%CI: 3.0−6.5) of those with no gain (p = 0.0004). 
Median OS of patients with AR CN gain was 6.1 (95%CI: 3.4−8.6) vs. 14.1 months 
(95%CI: 8.2−20.5) of those with no gain (p = 0.0003). At multivariate analysis, PSA 
decline ≥ 50% and AR CN showed a significant association with PFS (p = 0.008 and 
p = 0.002, respectively) and OS (p = 0.009 and p = 0.001, respectively). These findings 
indicate that the detection of circulating AR CN gain is a promising non-invasive 
biomarker for outcome prediction to enzalutamide treatment in CRPC patients.
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symptomatic CRPC [6, 7]. These promising results lead to 
the increasing use of enzalutamide. Therefore it becomes 
essential to better understand the mechanisms of drug 
resistance to select patients who will really experience a 
treatment benefit in terms of PFS and OS. 
AR axis is one of the most important actors in 
acquiring resistance to androgen targeting therapies. It has 
been shown that studying specific AR-related alterations 
could represent an optimal chance for finding predictive 
markers [8]. Circulating cell free DNA (cfDNA) is a 
promising, non-invasive source of molecular biomarkers 
and constitutes a “liquid biopsy” providing a genomic 
landscape of the cancer at the time of sample taking 
[9]. For this reason, many efforts have been made for 
studying aberrations, such as copy number alterations or 
specific mutations of AR in cfDNA, also thanks to the 
advancement in next generation sequencing technologies 
[10, 11]. In recent studies, a significant association has been 
reported between AR copy number (CN) in cfDNA and the 
clinical outcome of metastatic CRPC patients treated with 
abiraterone [8, 12]. We here aimed to test the association 
between AR CN in cfDNA and resistance to enzalutamide 
in a cohort of 59 CRPC patients treated with enzalutamide 
after docetaxel. 
results
AR copy number gain in crPc
Fifty-nine patients with metastatic CRPC were 
treated with enzalutamide between August 2012 and 
November 2015 and serum samples were collected at 
starting of treatment. Serum DNA was extracted and was 
tested for AR CN. Median DNA concentration was 4.5 ng/µl 
(range: 2–23.7 ng/µl). AR gene was gained in 21 (36%) 
patients. Approach sensitivity was previously tested [12]. 
Clinical characteristics are reported in Table 1. Higher 
median baseline PSA, alkaline phosphatase and lactate 
dehydrogenase levels were significantly associated with AR 
CN gain (p = 0.007, p = 0.003, p = 0.0009, respectively). 
Nine out of 28 (32%) patients previously treated with 
abiraterone had AR gain. This frequency of AR gain was 
similar to the prevalence in patients who had not received 
abiraterone (39%) (p = 0.602), therefore the probability to 
find AR gain in patients with or without previous abiraterone 
treatment was the same (Table 1). The frequency of AR gain 
was similar in patients with response duration to androgen 
deprivation therapy less than 18 months (52%) vs. those 
with a response longer than 18 months (38%, p = n.s.). 
Association with PsA decline and clinical 
outcome
A PSA decline ≥ 50% was reported in 18 of the 59 
(31%) patients, 4 of 21 (19%) with AR gene gain and 14 of 
38 (37%) without AR gene gain (p = 0.260). A PSA decline 
≥ 90% was reported in 5 of the 59 (8%) patients, all cases 
without AR gene gain. 
At the time of the analysis, 54 of the 59 patients had 
progressive disease (PD) and 39 patients had died. Median 
PFS and OS for the overall population were 3.5 months (95% 
CI: 2.7–4.4) and 9.4 months (95% CI: 7.8–14.1), respectively. 
The median PFS of patients with AR gene gain was 2.4 
months (95% CI: 1.9–3.2) vs. 4.0 months (95% CI: 3.0–6.5) 
of those with no CN variation (p = 0.0004) (Figure 1). 
The median OS of patients with AR gene gain was 6.1 
months (95% CI: 3.4-8.6) compared to 14.1 months (95% 
CI: 8.2–20.5) for individuals with one copy of the gene 
(p = 0.0003) (Figure 2). Supplementary Figures S1 and S2 
show the PFS and OS curves, respectively, made for AR gain 
vs. non-gain in patients without abiraterone and AR gain vs. 
non-gain with previous abiraterone.
Raw hazard ratios for PFS and OS are summarized 
in Table 2. Univariate analysis showed a significant 
association for PFS and OS with patients previously treated 
or not with abiraterone, PSA decline and AR CN (Table 2). 
At multivariate analysis, the only factors which maintained 
the association with PFS and OS were PSA decline 
≥ 50% (p = 0.008 and p = 0.009, respectively) and AR CN 
(p = 0.002 and p = 0.001, respectively). We also analyzed 
the sensitivity and specificity of AR CN in PFS and OS 
(Supplementary Table S1).
dIscussIon
Analysis of cfDNA is a promising and minimally 
invasive approach for characterizing the tumor genome 
in CRPC patients [13, 14]. In this paper, we performed 
AR copy number analysis on cfDNA in CRPC 
patients treated with enzalutamide after docetaxel. 
The distribution of median baseline PSA, alkaline 
phosphatase and lactate dehydrogenase levels were 
significantly higher in patients with AR CN gain, even 
if a cause-effect relationship cannot be established. 
Detection of AR gain in pretreatment cfDNA was 
significantly associated with treatment resistance and with 
shorter PFS and OS. 
This study highlighted AR gain as an independent 
biomarker from univariate and multivariate analyses 
for PFS and for OS. Moreover the multivariate analysis 
demonstrated PSA decline ≥ 50% could be a predictor of 
higher PFS and OS. The lack of association between AR 
CN gene and PSA response rate could have an explanation 
in possible changes of tumor biology during enzalutamide 
that were not present before treatment (e.g. neuroendocrine 
differentiation), even if a bias due to the small sample size 
needs to be considered [15, 16]. 
Currently, the sequential treatment is a hot topic of 
CRPC because of increasingly availability of survival-
prolonging agents arising the importance of patient selection 
to improve CRPC management. We here selected a cohort 
of patients who had all received docetaxel and, in 48% of 
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cases, also abiraterone. As expected, we therefore observed 
a shorter PFS and OS and lower response rate than reported 
in the chemotherapy-naïve setting. Our study supported 
the use of AR gain to select patients for enzalutamide but 
requires repeating in cohorts of patients with different 
clinical history to confirm that the association with outcome 
is maintained. Interestingly, prior use of abiraterone was no 
associated with a higher prevalence of AR gain, in keeping 
with our previous study that reported no significant change 
in AR status in sequential samples to progression [8]. 
To allow analysis of all our patients treated in early 
access program, we used serum samples. Due to concerns 
with increased leukocyte DNA release, we have more 
recently collected plasma for cfDNA studies. Increased 
levels of normal DNA could reduce our ability to detect 
AR CN gain clones and thus, reduce the difference we 
observed between AR gain and normal cancers. Overall, 
our observation may therefore be shown to be even more 
significant in future studies.
The only univariate analysis for PFS and OS showed 
a significant inverse association with prior abiraterone 
treatment. This confirms the limited antitumor activity 
of enzalutamide following abiraterone in metastatic CRPC 
patients irrespective of prior docetaxel use [17]. However, 
abiraterone before enzalutamide treatment and the number 
of previous chemotherapeutic lines did not influence the 
table 1: Patient characteristics
characteristics no. cases (%)
Ar
p-valuen A
no (%) no (%)
Total 59 (100) 38 (100) 21 (100) -
Median age, y [range] 75 [43–91] 75 [43–91] 74 [66–87] 0.715
Gleason Score
 6–7 20 (34) 14 (37) 6 (28)
0.806 8–9 30 (51) 20 (53) 10 (48)
 Unknown 9 (15) 4 (10) 5 (24)
ECOG PS
 0–1 56 (95) 36 (95) 20 (95)
0.934
 2 3 (5) 2 (5) 1 (5)
Visceral metastases
 No 51 (86) 32 (84) 19 (90)
0.504
 Yes 8 (14)   6 (16)  2 (10)
No. of previous chemotherapeutic lines
 1 21 (36) 15 (39)   6 (29)
0.406
 2 or more 38 (64) 23 (61) 15 (71)
Previous abiraterone treatment
 No 31 (52) 19 (50) 12 (57)
0.602
 Yes 28 (48) 19 (50) 9 (43)
Median baseline PSA level,  ng/mL [range] 68.2 [0.6–4351] 40.5 [0.6–4351] 182.0 [19.8–1443] 0.007
Median baseline ALP level,  mU/mL [range] 125 [32–6000] 100 [32–313] 416  [73–6000] 0.003
Median baseline LDH level,  mU/mL [range] 204 [122–1808] 194 [122–459] 272 [144–1808] 0.0009
AR, androgen receptor; N, normal; A, amplified; ECOG, Eastern Cooperative Oncology Group; PS, performance status; PSA, 
prostate-specific antigen, ALP, alkaline phosphatase; LDH, lactate dehydrogenase.
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frequency of AR CN variation at baseline. These evidences 
confirmed the lack of changes in AR status during 
hormonal treatment identified in circulating tumor DNA 
from 44 CRPC patients treated with abiraterone [8]. 
In addition, among clinical features of prostate 
cancer, the presence of visceral metastases has been 
evaluated in this paper: no correlation with AR CN 
frequency was observed. Conversely, the univariate 
analysis revealed that the presence of visceral metastases 
had a significant negative effect only on OS as well as we 
have shown in our previous work of 256 CRPC patients 
treated with abiraterone after docetaxel [18]. 
The small sample size, the retrospective nature of 
the analysis and the absence of an independent validation 
set represented the main limitations of our study. 
Consequently, our results should be considered preliminary 
Figure 1: Progression free-survival according to AR cn. 
Figure 2: overall survival according to AR cn.
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and hypothesis-generating. It can be hypothesized that 
enzalutamide-resistant patients with AR CN gain may 
benefit in terms of survival from chemotherapy and from 
other therapies that do not target AR signaling. Previously, 
several studies have already demonstrated that AR CN gain 
together with somatic point mutations were correlated with 
worse clinical outcome in CRPC patients [8, 10, 12, 19]. 
Identifying clinical and molecular factors predictive 
of response to enzalutamide remains a high priority for 
future research. Recently, Antonarakys et al. [20] have 
demonstrated that a splice variant of AR, ARV7, found 
in circulating tumor cells, was strongly associated with 
a poor outcome in patients treated with abiraterone or 
enzalutamide. We believe that also the evaluation of AR 
CN variation could have a similar important impact in 
guiding clinical decision in CRPC patients. 
In conclusion, AR CN variation seems to be a 
biomarker potentially valid from an analytical point of 
view and pave the way for a further clinical validation in 
prospective studies on larger number of patients.
MAterIAls And Methods
Patient cohort 
Patients with metastatic CRPC without 
neuroendocrine differentiation in the primary tumor 
after at least one chemotherapeutic treatment including 
docetaxel and treated with enzalutamide were included in 
this retrospective evaluation in a cohort of patients collected 
prospectively to study. Additional selection criteria included 
Eastern Cooperative Oncology Group (ECOG) performance 
status ≤ 2; adequate cardiac, hepatic, renal and bone marrow 
function; serum potassium level ≥ 3.5 mmol/L; and ongoing 
androgen deprivation therapy with serum testosterone 
< 50 ng/dL. The protocol was approved by the Institutional 
Review Board. Written informed consent was obtained from 
all patients. 
Treatment consisted of enzalutamide 160 mg 
daily, that was given continuously until evidence of PD 
or unacceptable toxicity. Baseline serum PSA levels 
were typically measured in the week before starting 
enzalutamide treatment. All recorded PSA test and scan 
results were collected for these patients: PSA was usually 
evaluated every 4 weeks for serologic response and imaging 
investigations as clinically indicated. The Prostate Cancer 
Working Group 2 (PCWG2) criteria were used to define 
response and progression [21]. However, in clinical practice 
deterioration, in clinical conditions and/or radiologic 
progression according to local radiologist evaluation were 
also criteria sufficient to establish PD and discontinuation 
of enzalutamide treatment.
cn analysis
Serum DNA was extracted with QIAamp DNA 
Mini Kit (Qiagen, Milan, Italy). DNA was quantified by 
spectrophotometric evaluation (NanoDrop® ND-1000, 
Celbio, Milan, Italy). CN analyses were performed by a 
duplex TaqMan real-time PCR assay (Applied Biosystems, 
Foster City, CA, USA) for AR gene and 2 different reference 
genes: RNaseP (TaqMan Copy Number Reference Assay) 
and AGO1 (ID: Hs02320401). Samples analysis was 
performed as previously described [12]. For AR, the cutoff 
values were > 1.5 for amplification. Data were also analyzed 
by Digital PCR QuantStudio® 3D System. We performed 
an absolute quantification of target and reference gene for 
each sample. 
statistical analysis
PFS was defined as the time between the first day of 
enzalutamide therapy and the date of PD or death. Patients 
without PD at database closure were censored at the final 
follow up. OS was defined as the time between the first 
day of enzalutamide and the date of death from any cause 
or censored at the date of the last follow-up visit.
The association between CN gain and clinical 
outcome was evaluated by the Kaplan-Meier method and 
log-rank test. A Cox regression model was used to estimate 
hazard ratios (HR) and 95% confidence intervals (CI) for 
PFS and OS. The multivariable Cox models included all 
factors that were significantly associated in the univariate 
models. All P-values were two-sided and a P < 0.05 was 
table 2: univariate analysis for progression-free survival and for overall survival
Progression-free survival overall survival
raw hr (95%cI) p raw hr (95%cI) p
Visceral metastases yes vs. no 1.57 (0.72−3.41) 0.257 2.44 (1.11−5.37) 0.027
no. of previous chemo lines ≥ 2 vs. 1 1.67 (0.94−2.99) 0.081 2.24 (1.09−4.63) 0.029
Previous abiraterone yes vs. no 1.97 (1.13−3.46) 0.017 2.41 (1.21−4.78) 0.012
PSA decline ≥ 50% no vs. yes 3.23 (1.71−6.10) 0.0003 3.52 (1.59−7.79) 0.002
AR cn variation A vs. N 2.79 (1.55−5.02) 0.0006 3.23 (1.64−6.35) 0.0007
PSA, prostate-specific antigen; AR, androgen receptor; CN, copy number; A, amplified; N, normal.
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considered statistically significant. Statistical analyses were 
performed with SAS 9.3 software (SAS Institute, Cary, NC).
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